Blog

  • ‘Most New Investors Are All Over The Map,’ How Establishing A ‘Buy Box’ Can Lead To Financial Independence

    ‘Most New Investors Are All Over The Map,’ How Establishing A ‘Buy Box’ Can Lead To Financial Independence

    Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

    In his early days as a real estate investor, Mike Zuber started to establish a set of criteria for the types of properties he’d consider buying. Among other things, he wanted single-family homes, with three to four bedrooms, in specific zip codes in Fresno, California. By sticking to that list, he told Business Insider, he was able to scale to more than 100 cash-flowing units, which allowed both him and his wife to quit their full-time jobs.

    This strategy, known as the “buy box” strategy, has allowed many new investors to gain a foothold in the industry and grow their portfolios.

    Don’t Miss:

    “Most new investors are all over the map,” Zuber told BI. “The first step any new investor needs to do is focus. If you’re going to be a buy-and-hold investor in a new area, get a buy box and make it hyper-focused.”

    There are several steps experts suggest taking when beginning to define your buy box. The first is to drive through various neighborhoods, attend open houses, and look at as many existing rental properties as you can. This will allow you to get a feel for the area, as well as the demand and type of resident you’re likely to attract.

    Next, they suggest doing your research. Looking into the area’s plans for infrastructure, employment growth, and community growth can help determine the potential future value of your home, they told BI. So spending a few hours digging up a city or county’s 10-year strategic growth plan is well worth your time.

    Trending: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.

    “Being a bit more rigorous about it can really pay dividends,” Grant Sabatier, a financially independent real estate investor with properties in New York City, told BI. “That’s what I did: I was laser focused on a five-block by four-block radius for a six-month period and then knew immediately when there was a deal that was perfect based on my criteria.”

    “The more you know your buy box, the better your chances are at finding a great deal,” Zuber told BI. “You can’t be casual. It has to be purposeful and intentional.”

    For Zuber, a great deal is one that has high cash-on-return, or the annual return he makes on a property in relation to how much he spends on that property over the course of a year.

    Continue Reading

  • How Much Protein Do You Actually Need?

    How Much Protein Do You Actually Need?

    “Those that are trying to lose weight may want a higher protein intake to help with muscle retention,” he said. Physical activity also plays a huge role: If you’re lifting weights, that presents a need to increase your protein intake—same…

    Continue Reading

  • Motorola’s Razr Ultra and the Marshall Emberton II top this week’s best deals

    Motorola’s Razr Ultra and the Marshall Emberton II top this week’s best deals

    If you’ve been thinking about buying a foldable phone that truly stands out, few models can rival the 2025 Motorola Razr Ultra, which is currently on sale at Amazon and Best Buy with 16GB of RAM and 512GB starting at $999.99 ($300 off), its…

    Continue Reading

  • Meghana Reddy Mareddy wins Egypt International 2025 badminton title

    Meghana Reddy Mareddy wins Egypt International 2025 badminton title

    Indian shuttler Meghana Reddy Mareddy won the women’s singles title at the Egypt International 2025 badminton tournament in Cairo on Saturday.

    The 21-year-old Meghana Reddy, 179th in the badminton rankings and seeded seventh, defeated…

    Continue Reading

  • Federica Brignone’s ‘impossible challenge’ in Milano Cortina 2026 season

    Federica Brignone’s ‘impossible challenge’ in Milano Cortina 2026 season

    Federica Brignone hasn’t set any finish line to her 2026 season. There isn’t one because she doesn’t want to set one for herself in the season leading up to Milano Cortina 2026 and the chance to compete in the Olympic Winter Games on home…

    Continue Reading

  • It’s Qwen’s world and we get to live in it, on CAISI’s report, & GPT-OSS update

    It’s Qwen’s world and we get to live in it, on CAISI’s report, & GPT-OSS update

    Before getting into the latest artifacts, there are a couple of pieces of crucial open ecosystem we have to cover.

    First, the Center for AI Standards and Innovation (CAISI) released a report that observed the ecosystem and evaluated DeepSeek 3.1…

    Continue Reading

  • Stem Cell Textbooks Challenged by “Immortal” Flatworm – SciTechDaily

    1. Stem Cell Textbooks Challenged by “Immortal” Flatworm  SciTechDaily
    2. Flatworm Stem Cells Regenerate Through Contactless Communication  the-scientist.com
    3. This Tiny Worm May Be the Key to Human Limb Regeneration  VICE
    4. Flatworms defy stem cell…

    Continue Reading

  • Listening For Gravitational Waves In The Rhythm of Pulsars

    Listening For Gravitational Waves In The Rhythm of Pulsars

    At the dawn of time, so the theory goes, the cosmos underwent a flash of rapid expansion. Almost instantly the visible Universe grew from a volume smaller than a proton to a spherical region nearly two meters across. It’s a moment known…

    Continue Reading

  • Evaluating Valuation After FDA Breakthrough Therapy Designation for BPL-003

    Evaluating Valuation After FDA Breakthrough Therapy Designation for BPL-003

    Atai Life Sciences (NasdaqGM:ATAI) and its partner Beckley Psytech just received Breakthrough Therapy designation from the FDA for BPL-003, their investigational nasal spray for treatment-resistant depression. This recognition accelerates the path to potential approval and highlights excitement about new mental health therapies.

    See our latest analysis for Atai Life Sciences.

    Atai’s FDA breakthrough news supercharged momentum that was already building. The share price has spiked 303% year-to-date, and the 1-year total shareholder return is an eye-popping 404%. With fresh capital raised through a $130 million equity offering and continued sector-wide interest in psychedelic medicines, investors are clearly betting on both near-term catalysts and the company’s longer-term potential.

    If regulatory milestones like this have you curious about other breakthrough opportunities, this is a great time to explore the latest See the full list for free..

    With Atai’s massive rally, strong analyst buy ratings, and a price target well above current levels, investors are now asking whether the stock remains undervalued or if recent gains have already priced in the next stage of growth.

    Atai Life Sciences trades at a price-to-book ratio of 9.6x, placing it well above the typical level in the pharmaceutical industry and raising questions about how much growth is being priced in at $6.45 per share.

    The price-to-book ratio compares a company’s market value to its book value, providing a sense of how much investors are willing to pay for each dollar of assets. In pharmaceuticals, where early-stage R&D companies are often years from profitability, elevated price-to-book multiples can reflect either strong future expectations or indicate market exuberance.

    While Atai’s ratio trails the peer group average of 11.3x, it remains much higher than the broader US Pharmaceuticals industry average of 2.4x. This suggests investors have high expectations, but maintaining this premium may be challenging without substantial revenue growth or positive earnings developments to support this year’s performance.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-Book of 9.6x (OVERVALUED)

    However, weak profitability and the potential for slower revenue growth could quickly cool investor enthusiasm if expectations get ahead of fundamentals.

    Find out about the key risks to this Atai Life Sciences narrative.

    If you have your own perspective or want to dive deeper, you can examine the numbers and construct your own take in just a few minutes, or Do it your way.

    A great starting point for your Atai Life Sciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

    Now is the perfect moment to broaden your perspective and act on investment opportunities beyond Atai Life Sciences. You could miss tomorrow’s biggest winner if you only look in one place.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ATAI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Comet C/2025 R2 SWAN with messier 16 and Messier 17 – 17 Oct. 2025.

    Comet C/2025 R2 SWAN with messier 16 and Messier 17 – 17 Oct. 2025.

    The beautiful comet C/2025 R2 SWAN is putting a wonderful show out there, thanks to the deep-sky friends it is meeting.

    Comet C/2025 R2 SWAN with Messier 16 and Messier 17. 17 Oct. 2025.

    The image above comes from the average of five,…

    Continue Reading